Hepatocellular carcinoma and features of its development
https://doi.org/10.51793/OS.2025.28.2.005
Abstract
Background. Hepatocellular carcinoma is one of the most difficult medico-societal and economic problems in the world. In spite of profound studies in this sphere, hepatocellular carcinoma continuous to take a leading position among oncological diseases. This type of cancer is the fifth malignant tumors and the second leading course of cancer – related deaths. The analyses of science data confirms the importance of hepatocellular carcinoma pathogenesis, which isquite complex and depends on etiological factors. It leads to the improvement of diagnostic criteria and their standardizations to simplifying their adaption in clinical practice. In this regard, the carcinoma early diagnosis requires search for new more specific and sensitive biomarkers which in turn needs understanding of epigenetic changes that develop in the process of pathogenesis in order to be able to rely on them to search for the selection of optimal sensitive potential markers for prognosis and postoperative monitoring of a specific group of patients.
Objective. To analyze and systematize the references about special features of hepatocellular carcinoma pathogenesis in patients with
hepatitis types B and C for estimation of potential markers search, which will be enough sensitive, but economically profitable and available for prognosis and postoperative monitoring of these groups of patients.
Materials and methods. The methods of analysis, synthesis and generalization of scientific data are used in the current work. The searching of the references was conducted using the databases Scopus, Web of Science, PubMed, eLibrary.
About the Authors
R. A. Zubkov
Irkutsk Region Сancer Center
Россия
Россия
Roman A. Zubkov, Cand. of Sci. (Med), chief physician
32 Frunze St., Irkutsk, 664032
K. N. Zabobonin
Irkutsk State Medical University
Россия
Россия
Konstantin N. Zabobonin, student of the Medical Faculty
2 Krasnogo Vosstaniya str., Irkutsk, 664003
E. V. Simonova
Irkutsk State Medical University
Россия
Россия
Elena V. Simonova, Dr. of Sci. (Med), Professor of the Department of Microbiology, Virology and Immunology
2 Krasnogo Vosstaniya str., Irkutsk, 664003
E. R. Zubkova
Irkutsk State Medical University
Россия
Россия
Elizaveta R. Zubkova, student of the Medical Faculty
2 Krasnogo Vosstaniya str., Irkutsk, 664003
References
1. Wen N., Cai Y., Li F., Ye H., Tang W., Song P., Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022; 16 (1): 20-30. DOI: 10.5582/bst.2022.01061. Epub 2022 Feb 24. PMID: 35197399.
2. Kaprin A. D., Starinskij V. V., Shaxzadova A. O. Information on treatment of hepatic and intrahepatic bile duct cancer first registered in 2022. The state of oncological care for the Russian population in 2022. 2022; 1: 200-201. (In Russ.)
3. Tang A., Hallouch O., Chernyak V., Kamaya A., Sirlin C. B. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018; 43 (1): 13-25. DOI: 10.1007/s00261-017-1209-1. PMID: 28647765.
4. Mayberry J., Lee W. M. The Revolution in Treatment of Hepatitis C. Med Clin North Am. 2019; 103 (1): 43-55. DOI: 10.1016/j.mcna.2018.08.007. PMID: 30466675.
5. Ergasheva U. P. Etiology and molecular cellular mechanisms of carcinogenesis of hepatocellular carcinoma. Colloquium-Journal. 2020; 4: 52-53. (In Russ.)
6. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394-424. DOI: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020; 70 (4): 313. DOI: 10.3322/caac.21609. PMID: 30207593.
7. Crouchet E., Schuster C., Baumert T. F. Liver cell circuits and therapeutic discovery for advanced liver disease and cancer. C R Biol. 2021; 344 (3): 233-248. DOI: 10.5802/crbiol.64. PMID: 35786628; PMCID: PMC7613418.
8. Lombardi A., Mondelli M. U.; ESCMID Study Group for Viral Hepatitis (ESGVH). Hepatitis C: Is eradication possible? Liver Int. 2019; 39 (3): 416-426. DOI: 10.1111/liv.14011. Epub 2019 Jan 10. PMID: 30472772.
9. Roger S., Ducancelle A., Le Guillou-Guillemette H., Gaudy C., Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021; 45 (3): 101626. DOI: 10.1016/j.clinre.2021.101626. Epub 2021 Feb 23. PMID: 33636428.
10. Znoyko O. O., Klimova E. A., Yushchuk N. D., et al. Viral hepatitis. Clinic, diagnosis, treatment. Moscow: GEOTAR-Media, 2014. Р. 85-114. (In Russ.)
11. Kalinina O. V., Mukomolov S. L. Molecular epidemiology of hepatitis C. Viral hepatitis. 2000; 3: 9-15. (In Russ.)
12. Akimkin V. G., Konoplyova M. V., Semenenko T. A., Sokolova M. V., Suslov A. P., Tutel`yan A. V. Mechanisms of immunologic escape of hepatitis B virus. Vestnik RAMN. 2017; 6: 23-25. (In Russ.)
13. Gordejchuk I. V., Gordejchuk I. N., Zverkova E. A., Ilchenko L. Yu., Knyazhenceva A. K., Mixajlov M. I., Morozov I. A., Storozhakov G. I., Fedorov I. G. Latent hepatitis B: clinical significance and diagnostic problems. Arkhiv vnutrennei meditsiny. 2012; 4: 39-45. (In Russ.)
14. Ajbosynova S. B., Bajxozhaeva R. Zh., Iskakova A. M., Seralieva G.A. Clinical course of HBeAg-positive hepatitis B virus disease. Vestnik AGIUV. 2011; 1: 43-44. (In Russ.)
15. Ghouri Y. A., Mian I., Rowe J. H. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017; 16: 1. DOI: 10.4103/jcar.JCar_9_16. PMID: 28694740; PMCID: PMC5490340.
16. Naikhin A. N., Losev I. V. Role of conserved and hypervariable immunodominant immunodominant epitopes of internal proteins of influenza A viruses in the generation of cytotoxic T-cell immune response. Voprosy virusologii. 2015; 1: 11-15. (In Russ.)
17. Irshad M., Mankotia D. S., Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol. 2013; 19 (44): 896-909. DOI: 10.3748/wjg.v19.i44.7896. PMID: 24307784; PMCID: PMC3848138.
18. Narayanamurthy V., Jeroish Z. E., Bhuvaneshwari K. S., Samsuri F. Hepatitis C virus (HCV) diagnosis via microfluidics. Analitic Methods. 2021; 13 (6): 740-763. DOI: 10.1039/d0ay02045a. Epub 2021 Jan 29. PMID: 33511975.
19. Baikova I. E., Nikitin I. G., et al. Antiviral therapy of chronic hepatitis C: current state of the problem and prospects. Lechenie i profilaktika. 2012; 2 (3): 77-87. (In Russ.)
20. Wilkins T., Sams R., Carpenter M. Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. Am Fam Physician. 2019; 99 (5): 314-323. PMID: 30811163.
21. Aristanbekova M. S., Balmasova I. P., Malova E. S., Sepiashvili R. I. Mechanisms of viral pathogen interactions in patients coinfected with human immunodeficiency virus and hepatitis C virus. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2016; 5: 101-109. (In Russ.)
22. Ferri C. Mixed cryoglobulinemia. Nephrology (Saint-Petersburg). 2010; 1: 11-28. (In Russ.)
23. Mikhailov M. I., Nikolaeva L. I., Petrova E. V., Tokmalaev A. K., Finogenova M. P., Shibnev V. A. Antibodies to coat proteins E1 and E2 in people infected with hepatitis C virus. Epidemiologia i vakcinoprofilaktika. 2006; 1 (26): 18-23. (In Russ.)
24. Ashraf M. U., Iman K., Khalid M. F., Salman H. M., Shafi T., Rafi M., Javaid N., Hussain R., Ahmad F., Shahzad-Ul-Hussan S., Mirza S., Shafiq M., Afzal S., Hamera S., Anwar S., Qazi R., Idrees M., Qureshi S. A., Chaudhary S. U. Evolution of efficacious pangenotypic hepatitis C virus therapies. Med Res Rev. 2019; 39 (3): 1091-1136. DOI: 10.1002/med.21554. Epub 2018 Dec 2. PMID: 30506705.
25. Zeisel M. B., Lucifora J., Mason W. S., Sureau C., Beck J., Levrero M., Kann M., Knolle P. A., Benkirane M., Durantel D., Michel M. L., Autran B., Cosset F. L., Strick-Marchand H., Trépo C., Kao J. H., Carrat F., Lacombe K., Schinazi R. F., Barré-Sinoussi F., Delfraissy J. F., Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure. Gut. 2015; 64 (8): 1314-1326. DOI: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. PMID: 25670809.
26. Semenenko T. A. Cellular immune response in hepatitis C. Virusnye gepatity. 2000; 1: 18-22. (In Russ.)
27. Liu H. M., Gale M. Hepatitis C Virus Evasion from RIG-I-Dependent Hepatic Innate Immunity. Gastroenterol Res Pract. 2010; 2010: 548390. DOI: 10.1155/2010/548390. Epub 2011 Jan 17. PMID: 21274284; PMCID: PMC3026989.
28. Rio E., Mornex F., Maingon P., Peiffert D., Parent L. Hepatic tumours and radiotherapy. Cancer Radiother. 2022; 26 (1-2): 266-271. DOI: 10.1016/j.canrad.2021.08.013. Epub 2021 Dec 23. PMID: 34953707.
29. Saitta C., Pollicino T., Raimondo G. Occult Hepatitis B Virus Infection: An Update. Viruses. 2022; 14 (7): 1504. DOI: 10.3390/v14071504. PMID: 35891484; PMCID: PMC9318873.
30. Gusarev S. A., Nepomnyashhaya E. M. Current concept of pathogenesis. Liver cancer. Izvestiya vuzov. Severo-Kavkazskij region. Seriya: Estestvennye nauki. 2004; 4: 87-90. (In Russ.)
Review
For citations:
Zubkov R.A., Zabobonin K.N., Simonova E.V., Zubkova E.R. Hepatocellular carcinoma and features of its development. Lechaschi Vrach. 2025;(2):32-37. (In Russ.) https://doi.org/10.51793/OS.2025.28.2.005
Views:
102
JATS XML
Email this article 
